Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer

Arjun V. Balar, MD
Published: Tuesday, Jul 11, 2017



Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the approval of pembrolizumab (Keytruda) in bladder cancer.

The treatment landscape for bladder cancer has changed dramatically over the last 5 years, according to Balar. The entire field has shifted towards immunotherapy and there are now 5 drugs approved in the second line setting and 2 drugs approved in the first line setting.

In the future, the field needs to look beyond PD-1/PD-L1 antibodies and investigate novel combinations, states Balar.
 


Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the approval of pembrolizumab (Keytruda) in bladder cancer.

The treatment landscape for bladder cancer has changed dramatically over the last 5 years, according to Balar. The entire field has shifted towards immunotherapy and there are now 5 drugs approved in the second line setting and 2 drugs approved in the first line setting.

In the future, the field needs to look beyond PD-1/PD-L1 antibodies and investigate novel combinations, states Balar.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x